Arrowhead shares jump 18% on Phase 3 success of plozasiran

ARWR Arrowhead Pharmaceuticals Inc

$58.37 +0.41%

View chart & analysis →

CAPR -4.22%

1. 1Arrowhead Pharmaceuticals (ARWR) saw its stock surge 18% after releasing Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran in severe hypertriglyceridemia.
2. 2At 12 months, triglycerides dropped 79% and 81%, respectively, far exceeding the roughly 27% reduction in the placebo group, while the incidence of acute pancreatitis also fell at a statistically significant level versus placebo.
3. 3Already marketed as REDEMPLO, plozasiran is set to be submitted to the FDA for an sNDA within the year to expand its indication, with detailed results to be presented on August 30 at the European Society of Cardiology meeting in Munich.

Source InvestorsHub +1 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →